Join Excelya, where Audacity, Care and Energy define who we are and how we work. We believe in creating ambitious solutions and fostering an inclusive environment where collaboration and individual growth go hand in hand.

This role offers an exciting opportunity to support the analytical platforms used for the design and statistical analysis of clinical trial data. As a Business System Expert, you will act as the link between Biostatistics, Statistical Programming, IT, QA, and external vendors, ensuring the performance, compliance, and continuous improvement of critical clinical systems.

Key Responsibilities

Provide functional support and administration for analytical platforms, primarily SAS (Viya, Grid, Clinical) and related systems.
Act as the main interface between Biostatisticians, SAS Programmers, IT teams, QA, and external providers.
Manage incidents, track technical issues, and coordinate resolution activities.
Ensure compliance and maintain Computer System Validation (CSV) documentation.
Develop and maintain quality documentation in accordance with GxP requirements.
Deliver training and support to end users.
Participate in system upgrades, deployments, and validation activities.
Monitor platform usage and propose corrective and preventive actions when needed.
Support the assessment and framing of new system implementation projects.

Master's degree in Life Sciences, Engineering, Computer Science, Statistics, or related field.
2–5 years of experience in system administration, system support, or business systems management.
Proven experience with SAS platforms (SAS Viya, SAS Grid, SAS Analytics Platform, SAS Clinical).
Understanding of Biostatistics and Statistical Programming activities within clinical trials.
Experience with Computer System Validation (CSV) and validation documentation.
Knowledge of ICH-GCP, GxP, and clinical research processes.
Familiarity with Google Cloud is highly desirable.
Fluent English (written and spoken).

Why join us?

At Excelya, we combine a passion for science with the enthusiasm of teamwork to redefine excellence in healthcare.

Here's what makes us unique:

We are a young and ambitious healthcare company, bringing together 900 Excelyates, driven by the goal of becoming the leading mid-sized CRO in Europe, while offering the best employee experience.

Our "one-stop provider" service model—combining full-service, functional service provider, and consulting—allows you to grow through diverse and stimulating projects. By collaborating with leading experts, you will contribute to the development of scientific, operational, and human knowledge, all in service of improving the patient journey.

Excelling with kindness means evolving in an environment that values your natural talents, encourages boldness, pushes boundaries, and cultivates your potential, so that you can fully contribute to our shared mission.

About the company

Excelya provides contract research services to biotech, pharma, and medical device companies, handling the full clinical trial process from operations to data management and regulatory affairs. It offers flexible engagement models—Full-Service, Functional Service Provider (FSP), and Resourcing—so clients can outsource end-to-end trials or specific experts or teams. The company differentiates itself through a people-first culture and growth via acquisitions, building a broad European footprint with capabilities across multiple therapeutic areas. Its goal is to expand its European and global presence while supporting development from early stages through post-market activities, including pharmacovigilance and real-world evidence.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Boulogne-Billancourt, France

Founded

2014

Get referred to Excelya

See people who can refer or advise you

Simplify's Take

What believers are saying

Eurazeo's November 24, 2025 financing funds targeted acquisitions and European expansion.
Excelya says it wants European leadership, serving mid-sized pharma amid sovereignty-driven procurement.
OCT Europe 2026 highlighted AI, JCA readiness, and real-world evidence capabilities.

What critics are saying

Excelya posted 0 open roles on August 21, 2026, signaling stalled hiring.
Eurazeo debt financing increases integration pressure; poorly integrated acquisitions destroy margins by 2027.
A failed acquisition cycle traps Excelya between debt service and client defections by 2027.

What makes Excelya unique

Excelya combines Full-Service, FSP, and Resourcing across 28 countries, spanning Europe, the U.S., and India.
François Moisson and Frédéric Paqueville built a people-first CRO, now backed by Eurazeo since 2025.
Its integrated clinical, biometrics, regulatory, and medical writing stack reduces sponsor vendor fragmentation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 7%

2 year growth

↑ 7%

Excelya

Feb 23rd, 2026

Excelya Earns EcoVadis Bronze Medal in 2026 Review

Excelya earns EcoVadis Bronze Medal in 2026 review. Introduction. Excelya Group is proud to share that Excelya has been awarded the EcoVadis Bronze Medal following its 2025/2026 reassessment. This recognition places Excelya Group in the top 35% of companies evaluated and reflects its continued dedication to responsible, ethical, and sustainable business practices. This achievement is especially meaningful given two major changes in this year's evaluation process: the full integration of Scope 3 carbon footprint calculations, along with the shift to non-rounded scoring, provides a more precise and rigorous assessment framework. Its 2026 EcoVadis results. Despite the more rigorous criteria, Excelya Group achieved a score nearly identical to last year, demonstrating the strength and consistency of its CSR foundations * Environment: 78/100 * Ethics: 70/100 * Sustainable Procurement: 69/100 * Overall Score: 71/100 (84th percentile) * Labor & Human Rights: 68/100 What this means for its future? While Excelya Group is encouraged by these results, Excelya Group recognize that sustainability is a continuous journey. Looking ahead to 2026, Excelya Group is committed to advancing its CSR strategy even further through two key initiatives: * Comprehensive Carbon Footprint Assessment: Excelya Group is partnering with Ecodev to implement a structured and comprehensive carbon footprint assessment that will give Excelya Group deeper insights into its environmental impact across all scopes. * Science Based Targets Initiative (SBTi) Alignment: Excelya Group is working toward aligning its climate goals with the Science Based Targets initiative, ensuring its emissions reduction targets are grounded in climate science and contribute meaningfully to limiting global warming. Moving forward together. This Bronze Medal isn't just recognition of where Excelya Group is, it's the foundation for where Excelya Group is going. Sustainability isn't a side initiative; it's embedded in how Excelya Group operate, support its clients, and empower its people. As Excelya Group continue to strengthen its CSR commitments, Excelya Group stay focused on delivering excellence while caring for its planet, its teams, and its communities. Thank you to every Excelyate who helps make sustainability a true value at Excelya. To learn more about Excelya's CSR and sustainability efforts, learn more about Excelya's CSR and sustainability efforts.

Morgan, Lewis & Bockius LLP

Dec 5th, 2025

Eurazeo invests in European clinical research provider Excelya

Morgan Lewis has advised Eurazeo on its investment in Excelya, a European clinical research services provider. The deal sees Eurazeo join as a long-term investor alongside Excelya's management team. Eurazeo, a leading European investment group, manages €37.4 billion in diversified assets and supports over 600 mid-market companies. Excelya specialises in developing patient treatments and advancing scientific knowledge in clinical research. The Morgan Lewis team included partners Sophie Perus and Sebastien Pontillo, of counsel Thomas Lefebvre, and associates Baptiste Godmer, Charles Deffontaines and Camille Jannin. Financial terms of the investment were not disclosed.

MarketScreener

Nov 24th, 2025

EURAZEO SUPPORTS EXCELYA IN A NEW PHASE OF DEVELOPMENT

Eurazeo is joining Excelya, a European clinical research services provider, as a lead investor alongside its management team to support the Group in continuing its development and pursuing external...